The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Single App knock-in mouse models of Alzheimer’s disease
Abstract
Experimental studies of Alzheimer's disease have largely depended on transgenic mice overexpressing amyloid precursor protein (APP). These mice, however, suffer from artificial phenotypes because, in addition to amyloid β peptide (Aβ), they overproduce other APP fragments. We generated knock-in mice that harbor Swedish and Beyreuther/Iberian mutations with and without the Arctic mutation in the APP gene. The mice showed typical Aβ pathology, neuroinflammation and memory impairment in an age-dependent manner.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We elected to use the AppNL-G-F knock-in mouse model for this study as it expresses App under its endogenous promoter in a physiological manner with regards to both cell type and amount, and avoids the issue of APP overexpression and abnormal expression patterns.”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [33]
In the citing paper
“AppNL-G-F mice [C57BL/6-App<tm3(NL-G-F)Tcs> (No.RBRC06344)] were provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan [33].”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [33]
In the citing paper
“we employed APPNLGF knock-in mice that express a humanized and triple-mutated APP in the endogenous App locus to circumvent transgenic mouse artifacts.”
From Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease model mice (2024) · cites this paper as [34]
In the citing paper
“While novel APP knock-in models, such as APPNL, APPNL-F, or APPNL-G-F mice overproduce Aβ1–42 in the absence of potentially confounding APP overexpression [139], these mice still contain one or more independent FAD mutations, which might result in an abnormal Aβ conformation [140].”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [139]
In the citing paper
“By 6 months of age, App NL‐G‐F mice exhibit a substantial amyloid plaque burden in the brain”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“These were bred to the App NL‐G‐F AD‐like model to determine responses in the context of amyloid‐driven pathology (Saito et al. 2014).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“The App NL‐G‐F mice are characterized by progressive amyloid deposition from 2 months to cognitive decline by 6 months (Saito et al. 2014).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“The App NL‐G‐F knock‐in model, however, has physiological App expression levels, avoiding the overexpression artifacts found in other transgenic models”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“but is strongly biased toward very high Aβ42:40 ratios (~10–100:1) because of the familial mutations”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“In AppNL-G-F mice, which harbor all three mutations, Aβ amyloidosis is aggressive, and neuroinflammation is observed in subcortical structures as well as cortical regions [10–12].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“By contrast, AppNL mice that carry only the Swedish mutation produce significantly higher levels of Aβ40 and Aβ42 without overt AD-related brain pathology such as extracellular Aβ plaques or neuroinflammation [10, 11, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“alternative mouse models have been generated via knock-in (KI) of a humanized Aβ sequences harboring familial AD mutations (Swedish (NL), Beyreuther/Iberian (F), and Arctic (G)) in order to model Aβ amyloidosis without non-physiological overexpression of APP [10].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“By contrast, AppNL mice that carry only the Swedish mutation produce significantly higher levels of Aβ40 and Aβ42 without overt AD-related brain pathology such as extracellular Aβ plaques or neuroinflammation [10, 11, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“To overcome these issues, KI mouse models with familial AD mutations have been generated [10, 24, 31, 32].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“despite overproducing human Aβ40 and Aβ42 in their brains [10, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“These results are consistent with recent studies reporting negligible cognitive deficits and the lack of Aβ plaque formation in AppNL/NL mice (Fig. 6) [10, 11, 13, 14, 24].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“Both models express human APP at physiological levels.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“The AppNL-G-F and AppNL-F show neuropathology and hippocampus-dependent cognitive impairments at 6 or 18 months, respectively.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“Our result in female mice is consistent with the cognitive phenotype in the Y maze reported in this genotype25,42.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“Human APP knockin (KI) models develop robust Aβ pathology, yet do not exhibit artifacts associated with APP over-expression, such as elevated levels of APP cleavage products (Saito et al., 2014).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These studies all suffer because they exhibit artifacts arising from the over-expression APP (WT or mutant) and in some cases mutant presenilins (Balducci and Forloni, 2011; Saito et al., 2014; Sasaguri et al., 2017).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“Human MAPT knock-in models have also been developed, and these models produce tau pathology, but only very late in the murine life span (~15 months) (Saito et al., 2014; Sakakibara et al., 2018; Sasaguri et al., 2022).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“However, over-expressing APP and presenilin 1 cause effect resulting from the over-expression that are unrelated to the disease process (Saito et al., 2014; Sakakibara et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These mice develop robust plaque pathology beginning as early as 3 months of age, however they develop little tau pathology and little neurodegeneration (Saito et al., 2014; Sakakibara et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These patterns of labeling or Aβ and MAPT are consistent with prior studies of APPNL-G-F and P301S MAPT mice (Yoshiyama et al., 2007; Saito et al., 2014; Sasaguri et al., 2017; Apicco et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“As expected,15 22-month-old AppNL-G-F mice had robust AD-related pathology, including amyloid deposition and neuroinflammation (Figures 1C and 1D).”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“As suggested,15,20 App KI mice may model pre-clinical stages of AD, characterized by progressive amyloidosis and gliosis without prominent cognitive deterioration, tau pathology, or neurodegeneration.”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“Humanized App knockin (KI) and APP transgenic mouse models mimic certain aspects of AD pathogenesis, including progressive amyloidosis, gliosis, and neuroinflammation, as well as network hyperexcitability and cognitive impairment, albeit to different degrees of severity across models and paradigms.15-27”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“Whereas plaque deposition only increases by less than twofold between 9 and 12 months of age, it increases tenfold between 12 and 18 months (Saito et al., 2014).”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“By contrast, NHE6 ablation led to glial activation and decreased plaque load in ApoeAPOE4 (Sullivan et al., 1997) and AppNL-F (Saito et al., 2014) double knockin mice.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“The AppNL-F mouse model used in our study develops plaques at 12 months (Saito et al., 2014) in the presence of murine ApoE.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“In AppNL-F mice, plaques can be identified as early as 9 months of age.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“These mice, however, do not show cognitive impairments in spatial learning tests like Morris water maze (Saito et al., 2014) (own unpublished observations).”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“We show in a well-studied App knock-in mouse model (Saito et al. , 2014) the gradual establishment of a multicellular co-expressed gene response encompassing 57 Plaque-Induced Genes or PIGs in the microenvironments of amyloid plaques (Figure 5).”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Saito et al., 2014
In the citing paper
“App NL-G-F knock-in (Saito et al., 2014) mice express Swedish (KM670/671NL), Beyreuther/Iberian (I716F), and Arctic (E693G) mutations in the App gene under the endogenous promoter on the C57Bl/6J background.”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Saito et al., 2014
In the citing paper
“AD mice, in which APP with a humanised Aβ region containing 3 AD-related mutations (APPNL-G-F) is knocked in (49), to avoid artefacts associated with over-expressing APP, were crossed with NG2-DsRed mice in which pericytes express DsRed (19).”
From Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes (2019) · cites this paper as [49]
In the citing paper
“In contrast, knock-in of Swedish and Iberian mutations results in plaque development beginning at 6 months, and gliosis, synaptic alterations and memory impairment from 18 months [129].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
In the citing paper
“Additional knock-in of the Arctic mutation into these mice results in more rapid pathology development including plaque development beginning at 2 months that is more widespread throughout the brain and memory impairment from 6 months [129].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
In the citing paper
“In contrast, initial studies show that more physiological knock-in mouse models develop cognitive impairment many months after plaque development [129], which is more similar to humans.”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
Citations
Cites
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587
Self-citationAβ Secretion and Plaque Formation Depend on Autophagy
Nilsson, P., Loganathan, K., Sekiguchi, M., Matsuba, Y., Hui, K., Tsubuki, S., Tanaka, M., Iwata, N., Saito, T., & Saido, T. C. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.042 · Cited by 459
Self-citationSarnyai, Z., Sibille, E. L., Pavlides, C., Fenster, R. J., McEwen, B. S., & Tóth, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14731 · Cited by 396
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,333
Daniels, M. J. D., Lefèvre, L., Szymkowiak, S., Drake, A., McCulloch, L. J., Tzioras, M., Barrington, J., Dando, O., He, X., Mohammad, M., et al. (2023) · eLife · doi:10.7554/elife.85279 · Cited by 29
Self-citationEnzlein, T., Cordes, J., Munteanu, B., Michno, W., Serneels, L., Strooper, B. D., Hanrieder, J., Ivo Wolf, A., Chávez‐Gutiérrez, L., & Hopf, C. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c02585 · Cited by 28
Martín‐Flores, N., Podpolny, M., McLeod, F., Workman, I., Crawford, K., Ivanov, D. K., Leonenko, G., Escott‐Price, V., & Salinas, P. C. (2023) · eLife · doi:10.7554/elife.89453 · Cited by 27
Asymmetry of Fibrillar Plaque Burden in Amyloid Mouse Models
Sacher, C., Blume, T., Beyer, L., Biechele, G., Sauerbeck, J., Eckenweber, F., Deußing, M., Focke, C., Parhizkar, S., Lindner, S., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.242750 · Cited by 29
Cellular Biology of Tau Diversity and Pathogenic Conformers
Kang, S., Eskandari‐Sedighi, G., Hromádková, L., Safar, J., & Westaway, D. A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.590199 · Cited by 29
Olfactory impairment in men and mice related to aging and amyloid-induced pathology
Tzeng, W.-Y., Figarella, K., & Garaschuk, O. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02527-0 · Cited by 29
Cholinergic neurodegeneration in Alzheimer disease mouse models
Shekari, A., & Fahnestock, M. L. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819973-2.00013-7 · Cited by 30
St‐Pierre, M., VanderZwaag, J., Loewen, S. M., & Tremblay, M. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.932572 · Cited by 27
Julku, U. H., Xiong, M., Wik, E., Roshanbin, S., Sehlin, D., & Syvänen, S. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00398-w · Cited by 27
Mowry, F. E., Espejo‐Porras, F., Jin, S., Quadri, Z., Wu, L., Bertolio, M., Jarvis, R., Reynolds, C. R., Alananzeh, R., Bieberich, E., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106213 · Cited by 27
Wu, D., Bi, X., & Chow, H. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02987-4 · Cited by 31
Wu, J., Wu, A., Zhou, X., Khan, I., Zhang, R. L., Lo, H. H., Li, Q., Song, L., Yun, X. Y., Wang, H. M., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105697 · Cited by 27
Microglia as a cellular target of diclofenac therapy in Alzheimer’s disease
Stopschinski, B. E., Weideman, R. A., McMahan, D., Jacob, D. A., Little, B. B., Chiang, H.-S., Saez Calveras, N., & Stuve, O. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231156674 · Cited by 26
A fully automated home cage for long-term continuous phenotyping of mouse cognition and behavior
Ho, H., Kejzar, N., Sasaguri, H., Saito, T., Saido, T. C., Strooper, B. D., Bauža, M., & Krupic, J. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100532 · Cited by 26
Self-citationDynamic Microtubules in Alzheimer’s Disease: Association with Dendritic Spine Pathology
Pchitskaya, E. I., Zhemkov, V., & Борисович, Б. И. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918090080 · Cited by 27
Identification of Alzheimer’s disease–associated rare coding variants in the ECE2 gene
Liao, X., Cai, F., Sun, Z., Zhang, Y., Wang, J., Jiao, B., Guo, J., Li, J., Liu, X., Guo, L., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.135119 · Cited by 26
Sakakibara, Y., Hirota, Y., Ibaraki, K., Takei, K., Chikamatsu, S., Tsubokawa, Y., Saito, T., Saido, T. C., Sekiya, M., & Iijima, K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210385 · Cited by 26
Self-citationAlzheimer’s-Like Pathology at the Crossroads of HIV-Associated Neurological Disorders
Chemparthy, D. T., Kannan, M., Gordon, L., Buch, S. J., & Sil, S. (2021) · Vaccines · doi:10.3390/vaccines9080930 · Cited by 27
Amyloid fibril proteomics of AD brains reveals modifiers of aggregation and toxicity
Upadhyay, A., Chhangani, D., Rao, N. R., Kofler, J., Vassar, R. J., Rincón-Limas, D. E., & Savas, J. N. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00654-z · Cited by 27
Delvenne, A., Vandendriessche, C., Gobom, J., Burgelman, M., Dujardin, P., Nolf, C. D., Tijms, B. M., Teunissen, C. E., Schindler, S. E., Verhey, F. R. J., et al. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00555-3 · Cited by 27
Devi, L., & Ohno, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.037 · Cited by 28
Global cPILOT analysis of the APP/PS‐1 mouse liver proteome
Evans, A. R., Gu, L., Guerrero, R., & Robinson, R. A. S. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400149 · Cited by 26
Wang, S., Yabuki, Y., Matsuo, K., Xu, J., Izumi, H., Sakimura, K., Saito, T., Saido, T. C., & Fukunaga, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206986 · Cited by 26
Self-citationSasaki, K., Fujita, H., Sato, T. K., Kato, S., Takahashi, Y., Takeshita, Y., Kanda, T., Saito, T., Saido, T., Hattori, S., et al. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.151016 · Cited by 25
Self-citationMurphy, K. B., Hu, D., Wolfs, L., Rohde, S. K., Fauró, G. L., Geric, I., Mancuso, R., De Strooper, B., & Marzi, S. J. (2025) · Nature Communications · doi:10.1038/s41467-025-60099-4 · Cited by 25
Ruiter, M., Herstel, L. J., & Wierenga, C. J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200527 · Cited by 25
Tooth Loss Induces Memory Impairment and Gliosis in App Knock-In Mouse Models of Alzheimer’s Disease
Taslima, F., Jung, C., Zhou, C., Abdelhamid, M., Abdullah, M., Goto, T., Saito, T., Saido, T. C., & Michikawa, M. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201055 · Cited by 26
Self-citationBouter, Y., Liekefeld, H., Pichlo, S., Westhoff, A. C., Fenn, L., Bakrania, P., & Bayer, T. A. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02418-3 · Cited by 26
Abelein, A., & Johansson, J. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00040k · Cited by 25
Multifaceted Roles of Aquaporins in the Pathogenesis of Alzheimer’s Disease
Yamada, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076528 · Cited by 26
Armstrong, P., Güngör, H., Anongjanya, P., Tweedy, C., Parkin, E. T., Johnston, J., Carr, I., Dawson, N., & Clapcote, S. J. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01852-z · Cited by 25
Staging Alzheimer’s Disease in the Brain and Retina of B6.APP/PS1 Mice by Transcriptional Profiling
Chintapaludi, S. R., Uyar, A., Jackson, H. M., Acklin, C. J., Wang, X., Sasner, M., Carter, G. W., & Howell, G. R. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190793 · Cited by 25
Influence of Western diet and APOE genotype on Alzheimer's disease risk
Sullivan, P. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104790 · Cited by 26
Miller, S. R., Luxem, K., Lauderdale, K., Nambiar, P., Honma, P. S., Ly, K. K., Bangera, S., Bullock, M., Shin, J., Kaliss, N., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114870 · Cited by 24
Self-citationOhyagi, M., Ito, M., Iizuka-Koga, M., Mise-Omata, S., & Yoshimura, A. (2025) · Nature Communications · doi:10.1038/s41467-025-64503-x · Cited by 24
Faresjö, R., Sjöström, E. O., Dallas, T. D., Berglund, M. M., Eriksson, J., Sehlin, D., & Syvänen, S. (2024) · mAbs · doi:10.1080/19420862.2024.2410968 · Cited by 25
Animal Models of Alzheimer’s Disease
Newman, M., Kretzschmar, D., Khan, I., Chen, M., Verdile, G., & Lardelli, M. T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00040-1 · Cited by 25
Vitale, P., Pereira, A. R. S., Lupaşcu, C. A., Willem, M., Migliore, R., Migliore, M., & Marie, H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.668948 · Cited by 26
Watamura, N., Sato, K., Shiihashi, G., Iwasaki, A., Kamano, N., Takahashi, M., Sekiguchi, M., Mihira, N., Fujioka, R., Nagata, K., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm6155 · Cited by 25
Self-citationDistinct microglia alternative splicing in Alzheimer's disease
Lu, Y., Tan, L., Xie, J., Cheng, L., & Wang, X. (2022) · Aging · doi:10.18632/aging.204223 · Cited by 25
Amyloid-β in Alzheimer’s disease – front and centre after all?
Weglinski, C., & Jeans, A. F. (2022) · Neuronal Signaling · doi:10.1042/ns20220086 · Cited by 24
Andersson, E., Schultz, N., Saito, T., Saido, T. C., Blennow, K., Gouras, G. K., Zetterberg, H., & Hansson, O. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01196-8 · Cited by 26
Self-citationIs Drp1 a link between mitochondrial dysfunction and inflammation in Alzheimer’s disease?
Sbai, O., Bazzani, V., Tapaswi, S., McHale, J., Vascotto, C., & Perrone, L. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1166879 · Cited by 24
Nuñez‐Diaz, C., Andersson, E., Schultz, N., Pocevičiūtė, D., Hansson, O., Bank, T. N. B., Nilsson, K. P. R., & Wennström, M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01375-7 · Cited by 24
Biundo, F., d’Abramo, C., Tambini, M. D., Zhang, H., Prete, D. D., Vitale, F., Giliberto, L., Arancio, O., & D'adamio, L. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.165 · Cited by 25
Modality-Specific Impairment of Hippocampal CA1 Neurons of Alzheimer’s Disease Model Mice
Takamura, R., Mizuta, K., Sekine, Y., Islam, T., Saito, T., Sato, M., Ohkura, M., Nakai, J., Ohshima, T., Saido, T. C., et al. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.0208-21.2021 · Cited by 24
Self-citationvan der Spek, S. J. F., Gonzalez‐Lozano, M. A., Koopmans, F., Miedema, S. S. M., Paliukhovich, I., Smit, A. B., & Li, K. W. (2021) · Cells · doi:10.3390/cells10071588 · Cited by 24
Kundu, P., Stagaman, K., Kasschau, K. D., Holden, S. J., Shulzhenko, N., Sharpton, T. J., & Raber, J. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.791128 · Cited by 24
Arachidonic Acid Mobilization and Peroxidation Promote Microglial Dysfunction in Aβ Pathology
Lin, D., Gold, A., Kaye, S., Atkinson, J., Tol, M. J., Sas, A., Segal, B. M., Tontonoz, P., Zhu, J., & Gao, J. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.0202-24.2024 · Cited by 23
Aβ43 aggregates exhibit enhanced prion-like seeding activity in mice
Ruiz‐Riquelme, A., Mao, A., Barghash, M. M., Lau, H. H. C., Stuart, E., Kovács, G. G., Nilsson, K. P. R., Fraser, P. E., Schmitt‐Ulms, G., & Watts, J. C. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01187-6 · Cited by 23
Nies, S. H., Takahashi, H., Herber, C. S., Huttner, A. J., Chase, A., & Strittmatter, S. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101159 · Cited by 25
Age-Dependent Behavioral and Metabolic Assessment of AppNL−G−F/NL−G−F Knock-in (KI) Mice
Wang, S., Ichinomiya, T., Savchenko, P., Devulapalli, S., Wang, D., Beltz, G., Saito, T., Saido, T. C., Wagner, S. L., Patel, H. H., et al. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.909989 · Cited by 23
Self-citationZelek, W. M., Bevan, R. J., & Morgan, B. P. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.03.017 · Cited by 25
Chen, L., Saito, T., Saido, T. C., & Módy, I. (2018) · eNeuro · doi:10.1523/eneuro.0059-18.2018 · Cited by 27
Self-citationSutoko, S., Masuda, A., Kandori, A., Sasaguri, H., Saito, T., Saido, T. C., & Funane, T. (2021) · iScience · doi:10.1016/j.isci.2021.102198 · Cited by 23
Self-citationGenetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21
Mumford, P., Tosh, J., Anderle, S., Gkanatsiou Wikberg, E., Lau, G., Noy, S., Cleverley, K., Saito, T., Saido, T. C., Yu, E., et al. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.0521-22.2022 · Cited by 22
Self-citationEskandari-Sedighi, G., Daude, N., Gapeshina, H., Sanders, D. W., Kamali-Jamil, R., Yang, J., Shi, B., Wille, H., Ghetti, B., Diamond, M. I., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0215-7 · Cited by 22
Jiang, M., Zhao, D., Zhou, Y., Kong, W., Xie, Z., Xiong, Y., Li, Y., Zhao, S., Kou, X., Zhang, S., et al. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01994-0 · Cited by 24
Papanikolaou, A., Graykowski, D. R., Lee, B. I., Yang, M., Ellingford, R. A., Zünkler, J., Bond, S. A., Rowland, J. M., Rajani, R. M., Harris, S., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.04.010 · Cited by 23
Early Locus Coeruleus noradrenergic axon loss drives olfactory dysfunction in Alzheimer’s disease
Meyer, C., Niedermeier, T., Feyen, P., Struebing, F. L., Rauchmann, B., Karali, K., Gentz, J., Tillmann, Y., Landgraf, N. F., Rumpf, S.-L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62500-8 · Cited by 24
Jacob, S., Davies, G., Bock, M. D., Hermans, B., Wintmolders, C., Bottelbergs, A., Borgers, M., Theunis, C., Broeck, B. V., Manyakov, N. V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51928-w · Cited by 22
Pauls, E., Bayod, S., Mateo, L., Alcalde, V., Juan-Blanco, T., Sánchez‐Soto, M., Saido, T. C., Saito, T., Berenguer, A., Attolini, C. S., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00983-y · Cited by 23
Self-citationAntonino, M., Marmo, P., Freites, C. L., Quassollo, G., Sánchez, M. F., Lorenzo, A., & Bignante, E. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.852738 · Cited by 24
Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches
Farrell, C., Mumford, P., & Wiseman, F. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.909669 · Cited by 22
Barendrecht, S., Schreurs, A., Geißler, S., Sabanov, V., Ilse, V., Rieckmann, V., Eichentopf, R., Künemund, A., Hietel, B., Wussow, S., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01144-y · Cited by 25
Vera, D. M., Zhao, H., Bereczki, E., Rosell‐Valle, C., Shimozawa, M., Chen, G., de Fonseca, F. R., Nilsson, P., & Tambaro, S. (2023) · Biology · doi:10.3390/biology12060805 · Cited by 24
Self-citationBellio, T. A., Laguna-Torres, J. Y., Campion, M. S., Chou, J., Yee, S., Blusztajn, J. K., & Mellott, T. J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297289 · Cited by 23
Zelek, W. M., Bevan, R. J., Nimmo, J., Dewilde, M., Strooper, B. D., & Morgan, B. P. (2024) · Brain · doi:10.1093/brain/awae278 · Cited by 23
Gidyk, D. C., Deibel, S. H., Hong, N. S., & McDonald, R. J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00245 · Cited by 22
Sevlever, D., Zou, F., Ma, L., Carrasquillo, S., Crump, M., Culley, O. J., Hunter, T. A., Bisceglio, G. D., Younkin, L. H., Allen, M., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0015-x · Cited by 22
Cai, H., Wang, Y., He, J., Cai, T., Wu, J., Fang, J., Zhang, R., Guo, Z., Guan, L., Zhan, Q., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21515 · Cited by 22
Wang, W., Tanokashira, D., Fukui, Y., Maruyama, M., Kuroiwa, C., Saito, T., Saido, T. C., & Taguchi, A. (2019) · Nutrients · doi:10.3390/nu11081942 · Cited by 22
Self-citationde Vidania, S., Palomares-Pérez, I., Frank, A., Saito, T., Saido, T. C., Draffin, J. E., Szaruga, M., Chávez‐Gutiérrez, L., Calero, M., Medina, M., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.562581 · Cited by 22
Self-citationBiechele, G., Wind-Mark, K., Blume, T., Sacher, C., Beyer, L., Eckenweber, F., Franzmeier, N., Ewers, M., Zott, B., Lindner, S., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117707 · Cited by 24
Mahaman, Y. A. R., Huang, F., Embaye, K. S., Wang, X., & Zhu, F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.680118 · Cited by 22
Chen, L., Christenson Wick, Z., Vetere, L. M., Vaughan, N., Jurkowski, A., Galas, A., Diego, K. S., Philipsberg, P. A., Soler, I., Feng, Y., et al. (2023) · The Journal of Neuroscience · doi:10.1523/jneurosci.1204-23.2023 · Cited by 21
The Role of Neprilysin and Insulin-Degrading Enzyme in the Etiology of Sporadic Alzheimer's Disease
Morito, T., Hashimoto, S., Takamura, R., Watamura, N., Kakiya, N., Fujioka, R., Mihara, N., Sekiguchi, M., Watanabe-Iwata, K., Kamano, N., et al. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.2152-24.2025 · Cited by 22
Self-citationShinohara, M., Tashiro, Y., Shinohara, M., Hirokawa, J., Suzuki, K., Onishi‐Takeya, M., Mukouzono, M., Takeda, S., Saito, T., Fukumori, A., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201901028rr · Cited by 21
Self-citationThe Role of the Gut Microbiota and Microbial Metabolites in the Pathogenesis of Alzheimer’s Disease
Wang, Y. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220417005115 · Cited by 21
Broadbelt, T., Mutlu-Smith, M., Carnicero-Senabre, D., Saido, T. C., Saito, T., & Wang, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-26113-1 · Cited by 21
Self-citationTransgenic Mouse Models for the Study of Neurodegenerative Diseases
Marín‐Moreno, A., Canoyra, S., Fernández‐Borges, N., Espinosa, J. C., & Torres, J. M. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2801021 · Cited by 21
Huang, H. X., Inglese, P., Tang, J., Yagoubi, R., Correia, G. D. S., der Sluis, V. M. H.-V., Camuzeaux, S., Wu, V., Kopanitsa, M. V., Willumsen, N., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16042 · Cited by 22
Self-citationMatsubara, K., Okuda, M., Shibata, S., Miyaki, S., Ohkubo, T., Izu, H., & Fujii, T. (2017) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2017.1403883 · Cited by 21
Rosner, D., Sun, J., Cacace, R., Yee, A., Wagh, C., Rychkova, A., Dunlap, M., Gulbranson, D. R., Ibrahim, A., Wang, X., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.11.022 · Cited by 20
Experimental Models of Tauopathy – From Mechanisms to Therapies
Götz, J. J., & Götz, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_28 · Cited by 24
Brady, E. S., Griffiths, J., Andrianova, L., Bielska, M. H., Saito, T., Saido, T. C., Randall, A. D., Tamagnini, F., Witton, J., & Craig, M. T. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106151 · Cited by 20
Self-citationSchilling, S., Pradhan, A., Heesch, A., Helbig, A., Blennow, K., Koch, C., Bertgen, L., Koo, E. H., Brinkmalm, G., Zetterberg, H., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01577-y · Cited by 21
Lai, R., Fang, Q., Wu, F., Pan, S., Haque, K., & Sha, S. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1199656 · Cited by 20
Ito, S., Yagi, R., Ogata, S., Masuda, T., Saito, T., Saido, T. C., & Ohtsuki, S. (2023) · Fluids and Barriers of the CNS · doi:10.1186/s12987-023-00466-9 · Cited by 20
Self-citationIzuo, N., Watanabe, N., Noda, Y., Saito, T., Saido, T. C., Yokote, K., Hotta, H., & Shimizu, T. (2023) · Aging Cell · doi:10.1111/acel.13994 · Cited by 20
Self-citationPizzirusso, G., Preka, E., Goikolea, J., Aguilar-Ruiz, C., Rodriguez‐Rodriguez, P., Vázquez-Cabrera, G., Laterza, S., Latorre‐Leal, M., Eroli, F., Blomgren, K., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.04.009 · Cited by 21
Self-citationNeural circuits expressing the serotonin 2C receptor regulate memory in mice and humans
Liu, H., He, Y., Liu, H., Brouwers, B., Yin, N., Lawler, K., Keogh, J. M., Henning, E., Lee, D.-K., Yu, M., et al. (2024) · Science Advances · doi:10.1126/sciadv.adl2675 · Cited by 20
Xie, L., Sheehy, R. N., Muneer, A., Xiong, Y., Wrobel, J. A., Zhang, F., Park, K., Velez, J., Liu, J., Luo, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59128-z · Cited by 20
Differential susceptibility of striatal, hippocampal and cortical neurons to Caspase-6
Noël, A., Zhou, L., Foveau, B., Sjöström, P. J., & LeBlanc, A. C. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-017-0043-x · Cited by 20
Casadomé‐Perales, Á., Matteis, L. D., Alleva, M., Infantes-Rodríguez, C., Palomares-Pérez, I., Saito, T., Saido, T. C., Esteban, J. A., Nebreda, Á. R., de la Fuente, J. M., et al. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0496 · Cited by 20
Self-citationAladeokin, A. C., Akiyama, T. H., Kimura, A., Kimura, Y., Jitsuki‐Takahashi, A., Nakamura, H., Makihara, H., Masukawa, D., Nakabayashi, J., Hirano, H., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104603 · Cited by 23
Self-citationBiechele, G., Monasor, L. S., Wind-Mark, K., Blume, T., Parhizkar, S., Arzberger, T., Sacher, C., Beyer, L., Eckenweber, F., Gildehaus, F., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.261858 · Cited by 20
Casein Kinase 2 dependent phosphorylation of eIF4B regulates BACE1 expression in Alzheimer’s disease
Bettegazzi, B., Monasor, L. S., Bellani, S., Codazzi, F., Restelli, L. M., Colombo, A. V., Deigendesch, N., Frank, S., Saito, T., Saido, T. C., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04062-3 · Cited by 20
Self-citationPre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation
Biechele, G., Blume, T., Deußing, M., Zott, B., Shi, Y., Xiang, X., Franzmeier, N., Kleinberger, G., Peters, F., Ochs, K., et al. (2021) · Theranostics · doi:10.7150/thno.64022 · Cited by 20
Pinpointing the locus of GABAergic vulnerability in Alzheimer’s disease
Melgosa-Ecenarro, L., Doostdar, N., Radulescu, C. I., Jackson, J., & Barnes, S. J. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.06.017 · Cited by 20
Metadata
- Authors
- Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C.
- Affiliations
- RIKEN Center for Brain Science (JP)
- Corresponding author
- Saido, Takaomi C
- Venue
- Nature Neuroscience
- Published
- 2014-04-13
- Volume
- 17
- Issue
- 5
- Pages
- 661-663
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W2090620788
- Cited by
- 1,366
- References
- 26
- Citations by year
- 2026: 159 · 2025: 164 · 2024: 209 · 2023: 167 · 2022: 157 · 2021: 155 · 2020: 92 · 2019: 73 · 2018: 64 · 2017: 49 · 2016: 37 · 2015: 24 · 2014: 13
- FWCI
- 15.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (23680039, 26290019)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, knock-in mice, amyloid precursor protein, APP mutations, Swedish mutation, Arctic mutation, amyloid-beta pathology, neuroinflammation, memory impairment, age-dependent phenotype
- MeSH terms
- Age Factors, Alzheimer Disease, Analysis of Variance, Animals, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Humans, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Maze Learning, Mice, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
